Determine the necessary mass, volume, or concentration for preparing a solution.
Information
Malotilate Malotilate (NKK105) is a drug used for the treatment of liver cirrhosis. Malotilate is a liver protein metabolism improved compound, which selectively inhibit the 5-lipoxygenase .
In vitro
Malotilate at concentrations of 0.1–100 μM increases collagenase activity in a concentration-dependent manner in the multilayered cultures, but not in the monolayers. Malotilate increases the secretion of MMP-1 and MMP-3 in the wounded multilayered cultures, but not in the wounded monolayers. Malotilate significantly reduces the invasion of the RLE monolayer by c-SST-2 cells. Malotilate prevents the increase in permeability of the RLE monolayer by serum starvation. Malotilate suppresses tumour metastasis by intensifying the cell-to-cell contact of endothelial cells, thus preventing tumour cells from invading vascular endothelium.
In vivo
Malotilate suppresses pulmonary metastasis and lung metastasis in rats. Malotilate prevents increases in serum markers of type III and IV collagen synthesis as well as accumulation of the collagens, laminin and fibronectin in the liver of rats. Malotilate combined with CCl4 significantly decreases hydroxyproline accumulation in the liver of rat, liver prolyl 4-hydroxylase and liver and serum galactosylhydroxylysyl glucosyltransferase activities. Malotilate is also able to prevent the development of morphological changes in the liver of rats such as focal necrosis, fatty infiltration and inflammatory changes. Malotilate also normalizes almost completely the standard liver-function tests. Malotilate decreases CYP2E1 levels and increases CYP2B1 levels in hepatic microsomes of rats, while CYP1A expression is not changed.
Cell Data
cell lines:HeLa, MCF7, MV4-11 and A2780 cells
Concentrations:
Incubation Time:
Powder Purity:≥99%
| Solubilità | Solubility (25°C) In vitro |
|---|---|
| Punto di fusione (°C) | 61 °C |